Sign in →

Epic Test Code LAB101011 Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation

Additional Codes

ARUP: 0092420

Ordering Recommendation 

Monitor patient compliance.

Included Test

 

Component Test Code* Component Chart Name
0092419 Drug Screen Comments, Serum or Plasma
0092421 Cannabinoids, S/P, Screen
0092422 Cocaine, S/P, Screen
0092423 Opiates, S/P, Screen
0092424 Phencyclidine, S/P, Screen
0092425 Amphetamines, S/P, Screen
0092426 Barbiturates, S/P, Screen
0092427 Benzodiazepines, S/P, Screen
0092428 Methadone, S/P, Screen
0092430 Oxycodone, S/P, Screen
0093414 Methamphetamine, S/P, Screen
2013568 Buprenorphine, S/P, Screen

Specimen Type

Plasma, Serum

Preferred Specimen

Gray (sodium fluoride/potassium oxalate).

Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.

Alternate Specimen

Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Storage Requirements

Refrigerated

Stability

After separation from cells:
Ambient: 1 week
Refrigerated: 2 weeks
Frozen: 3 years

Transportation Needs

Transport Temperature: Refrigerated

Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.

 

Minimum Volume

3 mL Plasma or Serum

Cause of Rejection

Specimens exposed to repeated freeze/thaw cycles.
Separator tubes.
Plasma or whole blood collected in lt. blue (sodium citrate).
Hemolyzed specimens.

Reference Value

Drugs Covered and Cutoff Concentrations
Drugs/Drug Classes Screen
Amphetamines Effective August 17, 2020
20 ng/mL
Methamphetamine Effective August 17, 2020
20 ng/mL
Barbiturates Effective August 17, 2020
50 ng/mL
Benzodiazepines Effective August 17, 2020
50 ng/mL
Buprenorphine 1 ng/mL
Cannabinoids Effective August 17, 2020
20 ng/mL
Cocaine Effective August 17, 2020
20 ng/mL
Methadone Effective August 17, 2020
25 ng/mL
Opiates Effective August 17, 2020
20 ng/mL
Oxycodone Effective August 17, 2020
20 ng/mL
Phencyclidine Effective August 17, 2020
10 ng/mL

Interpretive Data

Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.
 

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Turnaround Time

1-2 days
Confirmation: 1-4 days

Additional Information

Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.

Methodology

Qualitative Enzyme-Linked Immunosorbent Assay/ Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

CPT Code

80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992

Last Updated

7-OCT-20